Corvus Pharma Initiates Phase 1b Trial of Soquelitinib for Hidradenitis Suppurativa

Corvus Pharmaceuticals has begun a Phase 1b clinical trial for its drug soquelitinib to treat hidradenitis suppurativa. The trial aims to show proof-of-concept and assess the drug's effects on Th17 biology.